Table 1.
Characteristics of patients
| Patient # | Disease | Treatment | Drug response | Time to relapse |
|---|---|---|---|---|
| 1 | Ph+ ALL | Dasatinib 100 mg | Relapse | 3 months |
| 2 | CML | Dasatinib 50 mg | Loss of CHR | 4 months |
| 3 | CML | Dasatinib 75 mg | MMR | – |
| 4 | CML | Dasatinib 100 mg | MMR | – |
| 5 | CML | Nilotinib 600 mg | MMR | – |
| 6 | CML | Imatinib 100 mg | MMR | – |
| 7 | CML | Dasatinib 100 mg | MMR | – |
| 8 | CML | Dasatinib 100 mg | MMR | – |
CHR, complete hematologic response; CML, chronic myeloid leukemia; MMR, major molecular response; Ph+ ALL, Philadelphiachromosome-positive acute lymphoblastic leukemia.